# Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

> **NCT06830759** · — · RECRUITING · sponsor: **AbbVie** · enrollment: 700 (estimated)

## Conditions studied

- Diffuse Large B-cell Lymphoma
- Follicular Lymphoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06830759
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-28
- **Primary completion:** 2031-09
- **Final completion:** 2031-09
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06830759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06830759, "Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06830759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*